# ESCUDDO Long Term Follow Up

> **NCT07706673** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **National Cancer Institute (NCI)** · enrollment: 13700 (estimated)

## Conditions studied

- Human Papillomavirus Infection
- Human Papillomavirus-Related Malignant Neoplasm

## Interventions

- **BIOLOGICAL:** Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
- **BIOLOGICAL:** Recombinant Human Papillomavirus Nonavalent Vaccine

## Key facts

- **NCT ID:** NCT07706673
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-08-11
- **Primary completion:** 2030-10-01
- **Final completion:** 2031-01-15
- **Target enrollment:** 13700 (ESTIMATED)
- **Last updated:** 2026-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07706673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07706673, "ESCUDDO Long Term Follow Up". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07706673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*